In the News

Date	Title
March 15, 2024	Evidence-Based Use of Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration
August 3, 2023	ASRS 2023: Russ Trenary, President and CEO at Outlook Therapeutics, shares update on work toward FDA approval for Bevacizumab
August 3, 2023	ASRS 2023: Outlook Therapeutics and Bevacizumab
April 11, 2023	Outlook Therapeutics’ board members Julia A. Haller, MD, and Gerd U. Auffarth, FEBO, MD named to The Ophthalmologist’s Power List
May 13, 2022	Outlook Therapeutics updates intravitreal bevacizumab path toward commercialization
January 28, 2022	Bevacizumab Biologics License Application Expected in Q1 For Treatment Of wetAMD
January 21, 2022	Ophthalmic bevacizumab effectively treats wet macular degeneration, NORSE TWO concludes
November 30, 2021	AAO 2021 Late Breakers: DAVIO and NORSE-2
November 18, 2021	Positive Phase 3 Data Reported for Wet AMD Formulation ONS-5010 / LYTENAVA
November 13, 2021	Bevacizumab Formulation Significantly Improves wAMD Vision Versus Ranibizumab in NORSE 2
November 13, 2021	Ophthalmic bevacizumab shows promising vision gain in wet AMD in phase 3 study
September 29, 2021	Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
September 28, 2021	Outlook Therapeutics reports positive 12-month safety data from Phase 3 NORSE TWO trial
August 3, 2021	Retina specialists may get ophthalmic formulation of bevacizumab
July 7, 2021	Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
May 31, 2021	Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment
May 28, 2021	Anti-VEGF Therapy: Past, Present and Future
May 27, 2021	Outlook Therapeutics moving toward FDA approval of bevacizumab-vikg for treatment of wet AMD
April 29, 2021	Outlook Therapeutics is bringing a treatment for retinal disease to the market at the right time
April 12, 2021	Outlook Therapeutics 'almost complete' with pivotal Phase 3 NORSE TWO trial to treat wet AMD
April 1, 2021	SUBSPECIALTY NEWS: Ophthalmic bevacizumab, add-on AMD therapy, gene therapy, and more
February 10, 2021	With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds
January 5, 2021	The Outlook on Getting Regulatory-Approved Bevacizumab to Market
December 9, 2020	Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
October 6, 2020	Spotlight Q&A: Outlook Therapeutics - Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval
January 7, 2019	Proactive Investors interview with Outlook Therapeutics CEO Larry Kenyon